# Study of Tecovirimat for Human Mpox Virus

> **NCT05534984** · PHASE3 · TERMINATED · sponsor: **National Institute of Allergy and Infectious Diseases (NIAID)** · enrollment: 719 (actual)

## Conditions studied

- MPOX

## Interventions

- **DRUG:** Tecovirimat Oral Capsule
- **DRUG:** Placebo for Tecovirimat
- **DRUG:** Tecovirimat Oral Capsule (Open Label)

## Key facts

- **NCT ID:** NCT05534984
- **Lead sponsor:** National Institute of Allergy and Infectious Diseases (NIAID)
- **Sponsor class:** NIH
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2022-09-08
- **Primary completion:** 2024-10-23
- **Final completion:** 2025-02-22
- **Target enrollment:** 719 (ACTUAL)
- **Why stopped:** DSMB recommendation due to statistical futility
- **Last updated:** 2026-02-10

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05534984

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05534984, "Study of Tecovirimat for Human Mpox Virus". Retrieved via AI Analytics 2026-07-19 from https://api.ai-analytics.org/clinical/NCT05534984. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*